Skip to main content
Clinical Trials/CTRI/2017/02/007857
CTRI/2017/02/007857
Completed
Phase 4

An active surveillance to monitor the real world safety in Indian patients prescribed nintedanib for the treatment of locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy

Boehringer Ingelheim India Pvt Ltd0 sites28 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Boehringer Ingelheim India Pvt Ltd
Enrollment
28
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
September 24, 2022
Last Updated
2 years ago
Study Type
Pms

Investigators

Sponsor
Boehringer Ingelheim India Pvt Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients \=18 years of age with locally advanced and/or metastatic NSCLC of stage IIIB or IV, or recurrent NSCLC and adenocarcinoma histology after relapse or failure of first line of chemotherapy who are newly prescribed nintedanib according to the package insert.
  • 2\. Willing to provide the informed consent
  • 3\. Patients in whom further visit/contact is possible during the planned period of active surveillance
  • 4\. Patients in whom information mentioned in the section 9\.2\.2\.2 of the protocol is available

Exclusion Criteria

  • 1\. Patients who have taken nintedanib before participation in the study
  • 2\. Patients who are positive for EGFR mutation
  • 3\. Patients who are positive for ALK rearrangements
  • 4\. Patients who are participating in a clinical trial

Outcomes

Primary Outcomes

Not specified

Similar Trials